無料プレビュー

Viking Therapeutics, Inc. (VKTX) · NASDAQ Capital Market

プロフィール

Viking Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders. The company's lead program, VK2735, is a dual GLP-1/GIP receptor agonist in Phase 3 trials for obesity and type 2 diabetes in both subcutaneous and oral formulations. Additional pipeline programs include VK2809 (a thyroid hormone receptor beta agonist for NASH/MASH), VK0214 (a TRß agonist for X-linked adrenoleukodystrophy), a DACRA program for obesity, and VK5211 (a SARM for hip fracture recovery). The company operates globally through clinical development and con

主要指標

株価: $27.73 (-2.84%)
時価総額: 32億ドル
PER（今期予想）: -6.0
PBR: 7.9
配当利回り: —
52週レンジ: $25.77 – $43.15
業種: Healthcare / Biotechnology
上場: NASDAQ Capital Market
構成銘柄: —

比較会社: VRTX Vertex Pharmaceuticals Incorporated、MRNA Moderna, Inc.、REGN Regeneron Pharmaceuticals, Inc.、ARGX argenx SE、SGEN Seagen Inc.、RVMD Revolution Medicines, Inc.、ONC BeOne Medicines AG、ALNY Alnylam Pharmaceuticals, Inc.

長期トレンド・直近動向・強気／弱気シナリオ・業績10年・バリュエーション・テクニカル・株主・役員・深掘り分析は会員向けです。

7日間無料で全文を読むログイン

次回決算: 2026-10-28 · 更新: 2026-10-09